Sk Biopharmaceuticals Co Ltd (326030) — Cash Flow Quality Index
Sk Biopharmaceuticals Co Ltd (326030) has a Cash Flow Quality Index of 0.64x as of December 2025. Operating cash flow of ₩87.00 Billion is below net income of ₩136.59 Billion, suggesting accrual-heavy earnings not yet converted to cash. Also explore 326030 total assets for the complete picture of this company's asset base.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Sk Biopharmaceuticals Co Ltd Cash Flow Quality Index (2021–2025)
Historical Cash Flow Quality Index for Sk Biopharmaceuticals Co Ltd across 3 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Sk Biopharmaceuticals Co Ltd tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Sk Biopharmaceuticals Co Ltd (2021–2025)
Year-by-year earnings quality comparison for Sk Biopharmaceuticals Co Ltd. For live market cap and the full company financial profile, see 326030 stock market capitalisation.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.66x | ₩176.33 Billion | ₩266.95 Billion | ▲ +67.6% |
| 2024 | 0.39x | ₩94.90 Billion | ₩240.74 Billion | ▲ +127.5% |
| 2021 | -1.43x | ₩-92.87 Billion | ₩64.85 Billion | — |